Irbesartán/hidroclorotiazida
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What Karvezide is and what it is used for
2.What you need to know before you start taking Karvezide
3.How to take Karvezide
4.Possible side effects
5.Storage of Karvezide
6.Contents of the pack and additional information
Karvezide is a combination of two active principles, irbesartan and hydrochlorothiazide.
Irbesartan belongs to a group of medications known as angiotensin-II receptor antagonists.
Angiotensin-II is a substance produced in the body that binds to blood vessel receptors, causing them to contract. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, relaxing blood vessels and reducing blood pressure.
Hydrochlorothiazide belongs to a group of medications (called thiazide diuretics) that increase the amount of urine eliminated, reducing blood pressure.
The two active principles of Karvezide act together to achieve a decrease in blood pressure greater than that obtained with each one separately.
Karvezide is used to treat high blood pressure, when treatment with only irbesartan or only hydrochlorothiazide does not provide adequate control of your blood pressure.
Do not take Karvezide
Warnings and precautions
Consult your doctor before starting to takeKarvezide andin any of the following cases:
- an angiotensin-converting enzyme inhibitor (ACEI) (for example enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.
- aliskiren.
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (such as potassium) at regular intervals.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Karvezide. Your doctor will decide whether to continue treatment. Do not stop taking Karvezide in monotherapy.
See also the information under the heading “Do not take Karvezide”.
If you are pregnant, if you suspect you may be pregnantor if you plan to become pregnant, you mustinform your doctor. It is not recommended to use Karvezideat the beginning of pregnancy (first 3 months), and in any case, it should not be administered after the third month of pregnancy, as it may cause serious harm to your baby(see section “Pregnancy”).
You must also inform your doctor:
The hydrochlorothiazide contained in this medication may cause positive results in doping control.
Children and adolescents
Karvezide should not be administered to children and adolescents (under 18 years old).
Use of Karvezide with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Diuretics, such as hydrochlorothiazide contained in Karvezide, may affect other medications. You should not take Karvezide with preparations containing lithium without your doctor's supervision.
Your doctor may need to modify your dose and/or take other precautions:
if you are taking an ACEI or aliskiren (see also the information under the headings “Do not take Karvezide” and “Warnings and precautions”).
You may need to have blood tests if you take:
You should also inform your doctor if you are taking other medications to lower your blood pressure, steroids, cancer medications, analgesics, medications for arthritis, or cholestyramine or colestipol resins to reduce cholesterol in the blood.
Taking Karvezide with food, drinks, and alcohol
Karvezide can be taken with or without food.
Due to the hydrochlorothiazide contained in Karvezide, if you drink alcohol while taking this medication, you may experience a greater sensation of dizziness when standing up, especially when getting up from a seated position.
Pregnancy, breastfeeding, and fertility
Pregnancy
You must inform your doctor if you are pregnant, if you suspect you may be pregnantor if you plan to become pregnant. Your doctor will usually advise you to stop taking Karvezide before becoming pregnant or as soon as you become pregnant and recommend taking another antihypertensive medication instead. It is not recommended to use Karvezide at the beginning of pregnancy and in any case, it should not be administered after the third month of pregnancy, as it may cause serious harm to your baby when administered from that point onwards.
Breastfeeding
Inform your doctor if you plan to start or are breastfeeding, as it is not recommended to administer Karvezide to women during this period. Your doctor may decide to administer a more suitable treatment if you want to breastfeed, especially for newborns or premature babies.
Driving and operating machines
It is unlikely that Karvezide will affect your ability to drive vehicles or operate machines. However, during hypertension treatment, you may occasionally experience dizziness or fatigue. If you experience these symptoms, consult your doctor before driving or operating machines.
Karvezide contains lactose. If your doctor has told you that you have an intolerance to certain sugars (e.g. lactose), consult with them before taking this medication.
Karvezide contains sodium. This medication contains less than 1 mmol of sodium (23 mg) per tablet, i.e. it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Dose
The recommended dose of Karvezide isone tabletper day. In general, your doctor will prescribe Karvezide when previous treatments you received have not sufficiently reduced your blood pressure. Your doctor will instruct you on how to switch from previous treatments to Karvezide.
Administration Form
Karvezide is administered byoral route.Tablets should be swallowed with a sufficient amount of liquid (e.g. a glass of water). You can take Karvezide with or without food. Try to take your daily dose at the same time each day. It is essential that you continue taking Karvezide until your doctor advises you otherwise.
The maximum blood pressure-lowering effect should be achieved within 6-8weeks after starting treatment.
If you take more Karvezide than you should
If you accidentally take too many tablets, contact your doctor immediately.
Children should not take Karvezide
Karvezide should not be given to children under 18years of age. If a child swallows some tablets, contact your doctor immediately.
If you forgot to take Karvezide
If you accidentally forget to take a dose, simply take your regular dose when it is due next. Do not take a double dose to compensate for the missed doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Karvezide can cause side effects, although not everyone will experience them.
Some of these side effects may be serious and require medical attention.
In rare cases, cases of skin allergic reactions (skin rash, urticaria) have been reported in patients treated with irbesartan, as well as localized inflammation in the face, lips, and/or tongue.If you experience any of the above symptoms or have difficulty breathing, stop taking Karvezide and contact your doctor immediately.
The frequency of the side effects listed below is defined using the following convention:
Frequent: may affect up to 1 in 10 people
Rare: may affect up to 1 in 100 people
The side effects reported in clinical studies for patients treated with Karvezide were:
Frequent side effects(may affect up to 1 in 10 people):
If any of these side effects cause you problems, consult your doctor
Rare side effects(may affect up to 1 in 100 people):
If any of these side effects cause you problems, consult your doctor
Side effects since the marketing of Karvezide
Since the marketing ofKarvezide, some side effects have been reported. The side effectsobserved with unknown frequencyare: headache, ringing in the ears, cough, alteration of taste, indigestion, joint and muscle pain, liver function alterations and kidney insufficiency, elevated levels of potassium in your blood, and allergic reactions such as skin rash, urticaria, swelling of the face, lips, mouth, tongue, or throat.Also, cases of jaundice (yellowing of the skin and/or white of the eyes) have been observed.
As with all combinations of two active principles, the side effects associated with each component cannot be excluded.
Side effects associated only with irbesartan
In addition to the side effects described above, chest pain, severe allergic reactions (anaphylactic shock), decreased red blood cell count (anemia - symptoms may include fatigue, headaches, difficulty breathing during exercise, dizziness, and paleness), and decreased platelet count (a blood cell essential for blood clotting) and low blood sugar levels have been observed.
Rare (may affect up to 1 in 1,000 people): intestinal angioedema: swelling in the intestine that presents symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Side effects associated with hydrochlorothiazide in monotherapy
Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or white of the eyes); pancreatitis characterized by severe upper abdominal pain, often with nausea and vomiting; sleep disturbances; depression; blurred vision; lack of white blood cells, which may lead to frequent infections, fever; decreased platelet count (blood cells essential for blood clotting), decreased red blood cell count (anemia) characterized by fatigue, headaches, shortness of breath during exercise, dizziness, and paleness; kidney disease; pulmonary alterations including pneumonia or fluid accumulation in the lungs; increased skin sensitivity to the sun; inflammation of blood vessels; a skin disease characterized by peeling of the skin all over the body; cutaneous lupus erythematosus, identified by a rash that may appear on the face, neck, and scalp; allergic reactions; muscle weakness and spasms; alteration of heart rhythm; reduction of blood pressure after a change in body position; swelling of salivary glands; high blood sugar levels; sugar in the urine; increases in some types of blood fats; high levels of uric acid in the blood, which may cause gout.
Very rare:Acute respiratory distress (symptoms include severe difficulty breathing, fever, weakness, and confusion).
Frequency «unknown»(Cannot be estimated from available data): Skin and lip cancer (non-melanoma skin cancer), decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal hemorrhage) or acute angle-closure glaucoma).
It is known that the side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.
Reporting of side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it ispossibleside effects that do not appear in this prospectus.You can also report them directly throughthenational notification system included in theAppendix V. By reporting side effects, you can contributeto providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after CAD. The expiration date is the last day of the month indicated.
Do not store at a temperature above 30°C.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Karvezide
Appearance of the product and contents of the pack
Karvezide 300 mg/12.5 mg film-coated tablets are orange in color, biconvex, oval in shape, with a trochead heart on one face and the number 2876 engraved on the other.
Karvezide 300 mg/12.5 mg film-coated tablets are available in blister packs containing 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. They are also available in unit dose blister packs of 56 x 1 film-coated tablet for hospital supply.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Responsible Person
SANOFI WINTHROP INDUSTRIE
1, rue de la Vierge
Ambarès & Lagrave
F-33565Carbon Blanc Cedex - France
SANOFI WINTHROP INDUSTRIE
30-36Avenue Gustave Eiffel
37100Tours - France
SANOFI-AVENTIS, S.A.
Ctra.C-35 (La Batlloria-Hostalric), km. 63.09
17404 Riells i Viabrea (Girona)
Spain
For further information about this medicinal product, please consult the representative of the marketing authorization holder in your country:
België/Belgique/Belgien Sanofi-aventis Belgium Tél/Tel:+32 (0)2 710 54 00 | Luxembourg/Luxemburg Sanofi Belgium Tél/Tel:+32 (0)2 710 54 00 (Belgique/Belgien) | |
Magyarország Sanofi-Aventis zrt., Magyarország Tel.: +36 1505 0050 | ||
Ceská republika Sanofi, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 | |
Danmark Sanofi A/S Tlf: +45 45 16 70 00 | Nederland Sanofi B.V. Tel:+31 20 245 4000 | |
Deutschland Zentiva Pharma GmbH Tel: 0800 52 52 010 Tel. aus dem Ausland:+49 69 305 21 131 | Norge sanofi-aventis Norge AS Tlf: +47 67 10 71 00 | |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Österreich sanofi-aventis GmbH Tel: +43 1 80 185 – 0 | |
Ελλ?δα Sanofi-Aventis Μονοπρ?σωπη AEBE Τηλ: +30 210 900 16 00 | Polska Sanofi Sp.z o.o. Tel.: +48 22280 00 00 | |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 | |
France Sanofi Winthrop Industrie Tél: 0 800 222 555 Appel depuis l’étranger : +33 1 57 63 23 23 Hrvatska Swixx Biopharma d.o.o. Tél: +38512078 500 | România Sanofi Romania SRL Tel: +40(0) 21 317 31 36 | |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 | |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 | |
Italia Sanofi S.r.l.. Tel: 800.536389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 | |
Κ?προς C.A. Papaellinas Ltd. Τηλ: +357 22741741 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 | |
Latvija Swixx Biopharma SIA Tel: +371 6616 47 50 | United Kingdom(Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0)800 035 2525 | |
Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Last update of the summary of product characteristics:
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.